Publications

Three-Month Tapering and Discontinuation of Long- Term, Low-Dose Glucocorticoids in Senior Patients with Rheumatoid Arthritis Is Feasible and Safe: Placebo-Controlled Double Blind Tapering After the Gloria Trial

AuthID
P-00Y-WWB

Author(s)

Almayali, AAH

Boers, M

Hartman, L

Opris, D

Bos, R

Kok, MR

Da Silva, JAP

Griep, E

Klaasen, R

Allaart, CF

Baudoin, P

Raterman, HG

Szekanecz, Z

Buttgereit, F

Masaryk, P

Lems, W

Smulders, Y

Cutolo, M

ter Wee, MM

Document Type

Article in Press

Year published

2023

Published

in ANNALS OF THE RHEUMATIC DISEASES, ISSN: 0003-4967

Indexing

Wos^®

Scopus^®

Pubmed^®

Google Scholar^®

Metadata
Sources

Publication Identifiers

DOI: 10.1136/ard-2023-223977

Pubmed: 37541762

Scopus: 2-s2.0-85168274077

Wos: WOS:001042183300001

Source Identifiers

ISSN: 0003-4967

Export Publication Metadata

Marked List

Add to Marked List

Info

At this moment we don't have any links to full text documens.

Three-Month Tapering and Discontinuation of Long- Term, Low-Dose Glucocorticoids in Senior Patients with Rheumatoid Arthritis Is Feasible and Safe: Placebo-Controlled Double Blind Tapering After the Gloria Trial

Useful Links

Get Help

Federated Authentication (Click on the image)

Three-Month Tapering and Discontinuation of Long- Term, Low-Dose Glucocorticoids in Senior Patients with Rheumatoid Arthritis Is Feasible and Safe: Placebo-Controlled Double Blind Tapering After the Gloria Trial

Useful Links

Get Help